Paul Crits-Christoph1, Hannah M Markell1, Robert Gallop2, Mary Beth Connolly Gibbons1, Bridget McClure3, John Rotrosen4. 1. a Department of Psychiatry , University of Pennsylvania , Philadelphia , PA , USA. 2. b Department of Mathematics , West Chester University , West Chester , PA , USA. 3. c Joint Clinical Trials Office , Weill Cornell Medical College , New York , NY , USA. 4. d Department of Psychiatry , New York University School of Medicine , New York , NY , USA.
Abstract
OBJECTIVE: The goal of the study was to evaluate whether enhanced normative feedback recovery curves are needed for treatment of substance use problems. METHOD: Patient predictors of outcome were examined using data from four substance abuse treatment clinics. RESULTS: Baseline severity of symptoms/functioning, employment, and craving were found to be associated with rate of change in symptoms/functioning. Several other variables were associated with rate of change in alcohol use, although in the opposite direction than found in efficacy trials. CONCLUSIONS: The results point to the complexity of designing feedback systems using normative recovery curves for those with substance use problems and highlight the important differences between real-world treatment of those with substance use problems compared to data from efficacy trials.
OBJECTIVE: The goal of the study was to evaluate whether enhanced normative feedback recovery curves are needed for treatment of substance use problems. METHOD:Patient predictors of outcome were examined using data from four substance abuse treatment clinics. RESULTS: Baseline severity of symptoms/functioning, employment, and craving were found to be associated with rate of change in symptoms/functioning. Several other variables were associated with rate of change in alcohol use, although in the opposite direction than found in efficacy trials. CONCLUSIONS: The results point to the complexity of designing feedback systems using normative recovery curves for those with substance use problems and highlight the important differences between real-world treatment of those with substance use problems compared to data from efficacy trials.
Authors: Paul Crits-Christoph; Mary Beth Connolly Gibbons; Jacques P Barber; Robert Gallop; Aaron T Beck; Delinda Mercer; Xin Tu; Michael E Thase; Roger D Weiss; Arlene Frank Journal: J Consult Clin Psychol Date: 2003-10
Authors: Paul Crits-Christoph; Sarah Ring-Kurtz; Jessica L Hamilton; Michael J Lambert; Robert Gallop; Bridget McClure; Agatha Kulaga; John Rotrosen Journal: J Subst Abuse Treat Date: 2011-10-29
Authors: Roger D Weiss; Margaret L Griffin; Carissa Mazurick; Benjamin Berkman; David R Gastfriend; Arlene Frank; Jacques P Barber; Jack Blaine; Ihsan Salloum; Karla Moras Journal: Am J Psychiatry Date: 2003-07 Impact factor: 18.112
Authors: Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman Journal: Arch Gen Psychiatry Date: 2008-02